Contract analysis

I. PRELIMINARY STATEMENT This case presents a straightforward question of contract interpretation that the Court can and should resolve on summary judgment: Does the Exclusive Distribution Agreement dated July 1, 2017 (the "EDA" or "Agreement") between Plaintiff Penterra Pharmaceuticals Corp. ("Penterra" or "Plaintiff") and Defendant Vantage Medical Distribution, LLC ("Vantage" or "Defendant") grant Vantage exclusive

II. STATEMENT OF FACTS The following facts are drawn from the parties' joint statement of undisputed material facts, the exhibits thereto, and the deposition transcripts produced during fact discovery, which concluded on January 14, 2022. Except where specifically noted, these facts are not in genuine dispute. A. The Parties Penterra Pharmaceuticals Corp. is a Delaware corporation that has been publicly traded on the

Section 2.3 of the EDA imposes a corresponding restriction on the Distributor's activities outside the Territory: "Distributor shall not actively solicit orders for, or deliver, the Products outside the Territory without Supplier's prior written consent." Ex. 2, § 2.3. This provision serves as an important complement to the territorial grant: while Section 2.1 grants Vantage exclusive rights within the Territory, Sec

Section 5.2 of the EDA establishes a minimum purchase commitment, requiring Vantage to purchase a minimum of $9.5 million of Oncalaris® per year, calculated at the wholesale acquisition cost ("WAC"). Ex. 2, § 5.2. The record demonstrates that Vantage exceeded this minimum commitment in every year of the Agreement's term: SUF ¶¶ 18-21; Ex. 6 (Vantage Purchase Records, produced as VANTAGE_00008412-08519). While Vantage

III. LEGAL STANDARD Under Massachusetts Rule of Civil Procedure 56(c) and Superior Court Rule 9A(b)(5), summary judgment is appropriate "if the pleadings, depositions, answers to interrogatories, and responses to requests for admission under Rule 36, together with the affidavits, if any, show that there is no genuine issue as to any material fact and that the moving party is entitled to a judgment as a matter of law.

IV. ARGUMENT A. The Plain Language of the EDA Limits the Territory to the Six New England States

1. Exhibit A Is Unambiguous The starting point for any contract interpretation dispute under Massachusetts law is the language of the contract itself. Seaboard Sur. Co. v. Gillette Co., 64 Mass. App. Ct. 59, 62 (2005). Where the contract language is "plain and free from ambiguity," the court must enforce the contract "according to the plain import of its terms." Id. Courts do not "add words to a contract that the par

Section 2.3 of the EDA provides further reinforcement of the territorial boundaries. That section provides that "Distributor shall not actively solicit orders for, or deliver, the Products outside the Territory without Supplier's prior written consent." Ex. 2, § 2.3. The very existence of Section 2.3 presupposes that there is an "outside the Territory" — i.e., that the Territory has defined boundaries beyond which Va

2. Vantage Cannot Expand Exhibit A Through a Casual Email Confronted with unambiguous contractual language that does not support its position, Vantage pins its hopes on the January 12, 2018 Kapoor Email. That email — Vantage's sole documentary basis for claiming tri-state distribution rights — reads in its entirety: "Don — good catching up yesterday. We're definitely open to exploring expansion into NY/NJ/PA once you

1. Section 13.1 Is Enforceable Under Massachusetts Law Even if the Kapoor Email could somehow be read as something more than a casual expression of interest — a reading that its plain language does not support — it would still be legally insufficient to modify the EDA because it fails to satisfy the requirements of Section 13.1. That section provides: "No amendment, modification, or waiver of any provision of this Ag

2. No Signed Written Instrument Exists Expanding the Territory The legal conclusion compelled by Section 13.1 is confirmed by the factual record. After extensive fact discovery — including the production of approximately 47,000 pages of documents by both parties, comprehensive interrogatory responses, and the depositions of four key witnesses — no signed written instrument amending Exhibit A or expanding the Territor

1. The EDA Is a Fully Integrated Agreement

Section 14.8 of the EDA contains a comprehensive merger and integration clause: "This Agreement, including all Exhibits, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior negotiations, representations, or agreements relating thereto, whether written or oral." Ex. 2, § 14.8. This clause establishes that the EDA is a fully integrated agreement — that

2. Vantage's Course-of-Dealing Argument Fails In addition to the Kapoor Email, Vantage has advanced the theory that Penterra's alleged failure to object to certain Vantage shipments to New York in late 2019, combined with the Kapoor Email, effected a modification of Exhibit A through course of dealing. This argument fails for multiple independent reasons. First, the course-of-dealing argument is foreclosed by Section

1. Breach of Contract (Count I of Counterclaims) Vantage's breach-of-contract counterclaim alleges that Penterra breached the EDA by seeking to appoint Meridian National Distributors, Inc. as a distributor for Oncalaris® and Renuvesta® in New York, New Jersey, Pennsylvania, and Maryland. According to Vantage, this action violated Vantage's exclusive distribution rights in the tri-state area. The fatal flaw in this cl

2. Breach of Implied Covenant of Good Faith and Fair Dealing (Count II of Counterclaims) Vantage's second counterclaim alleges that Penterra breached the implied covenant of good faith and fair dealing by attempting to appoint Meridian as a tri-state distributor, thereby purportedly depriving Vantage of the fruits of the EDA. Under Massachusetts law, every contract implies a covenant of good faith and fair dealing. U

3. Promissory Estoppel (Count III of Counterclaims) Vantage's third counterclaim asserts promissory estoppel, alleging that it reasonably relied on the Kapoor Email as a promise of territorial expansion and invested resources in tri-state distribution operations to its detriment. Under Massachusetts law, the elements of promissory estoppel are: (1) a promise; (2) that the promisor should reasonably have expected to i